44 results
424B5
HROW
Harrow Inc
19 Dec 22
Prospectus supplement for primary offering
4:50pm
pandemic on our financial condition, liquidity or results of operations; our ability to successfully implement our business plan; develop
424B5
HROW
Harrow Inc
14 Dec 22
Prospectus supplement for primary offering
5:29pm
to: the impact of the COVID-19 pandemic on our financial condition, liquidity or results of operations; our ability to successfully implement our business … , financial condition and stock price.
From time to time, including recently as a result of the COVID-19 pandemic, global credit and financial markets have
8-K
EX-99.1
HROW
Harrow Inc
14 Dec 22
Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to
6:45am
and uncertainties that could cause actual results to differ from those predicted include the continued impact of the COVID-19 pandemic and any future health
424B5
w8hiu6
14 Dec 22
Prospectus supplement for primary offering
6:44am
8-K
EX-99.1
c0jk9g6
14 Nov 22
Harrow Announces Third Quarter 2022 Financial Results
4:20pm
8-K
EX-99.2
gr34cwji00b2620dqnyy
14 Nov 22
Harrow Announces Third Quarter 2022 Financial Results
4:20pm
8-K
EX-99.1
q1xiq6r5gup8u o63q
5 May 22
Harrow Health Announces First Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
bn6menyldzb jq
10 Mar 22
Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results
4:30pm
8-K
EX-99.1
lyjjj2 9mwc8k121wlq
20 Dec 21
Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops
8:05am
8-K
EX-99.1
ps4ksfnipw0vm
9 Dec 21
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded
4:13pm
8-K
EX-99.1
gz75a6
9 Nov 21
Harrow Health Announces Third Quarter 2021 Financial Results
4:05pm
8-K
EX-99.2
n3m3a7abre8m08uxqib3
9 Nov 21
Harrow Health Announces Third Quarter 2021 Financial Results
4:05pm
8-K
EX-99.1
zay6z
2 Sep 21
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
xvateyar7ibc05bga
18 Aug 21
Harrow Health Acquires Ophthalmic Surgical Drug Candidate
7:30am